Mark Massaro
Stock Analyst at BTIG
(4.30)
# 342
Out of 5,146 analysts
185
Total ratings
50%
Success rate
17.48%
Average return
Main Sectors:
Stocks Rated by Mark Massaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDNA CareDx | Maintains: Buy | $25 → $26 | $18.82 | +38.15% | 6 | Feb 26, 2026 | |
| TEM Tempus AI | Maintains: Buy | $105 → $90 | $55.41 | +62.43% | 7 | Feb 25, 2026 | |
| WGS GeneDx Holdings | Maintains: Buy | $200 → $170 | $81.38 | +108.90% | 8 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $140 → $145 | $97.97 | +48.00% | 8 | Feb 20, 2026 | |
| XGN Exagen | Maintains: Buy | $15 → $10 | $3.80 | +163.16% | 6 | Feb 17, 2026 | |
| PSNL Personalis | Maintains: Buy | $12 → $13 | $9.03 | +43.96% | 5 | Feb 11, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Buy | $21 → $22 | $16.46 | +33.66% | 8 | Feb 6, 2026 | |
| IDXX IDEXX Laboratories | Maintains: Buy | $830 → $800 | $660.71 | +21.08% | 3 | Feb 3, 2026 | |
| MDXH MDxHealth | Reiterates: Buy | $7 | $3.55 | +97.18% | 10 | Dec 23, 2025 | |
| CSTL Castle Biosciences | Maintains: Buy | $38 → $50 | $31.88 | +56.84% | 6 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $71.41 | +124.06% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $260 | $216.10 | +20.31% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $129.76 | +23.30% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $103.25 | - | 20 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $4.57 | +53.17% | 3 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $2.5 | $1.47 | +70.07% | 4 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $6 → $9 | $9.71 | -7.31% | 7 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.79 | - | 4 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.15 | - | 8 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $21 | $10.17 | +106.49% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.28 | - | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.60 | - | 1 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $350 → $300 | $127.40 | +135.48% | 6 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $52 → $50 | $75.23 | -33.54% | 9 | Nov 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $112 | $211.10 | -46.94% | 10 | Jul 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $155 → $165 | $287.62 | -42.63% | 10 | May 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $22.70 | +252.42% | 9 | Sep 10, 2018 |
CareDx
Feb 26, 2026
Maintains: Buy
Price Target: $25 → $26
Current: $18.82
Upside: +38.15%
Tempus AI
Feb 25, 2026
Maintains: Buy
Price Target: $105 → $90
Current: $55.41
Upside: +62.43%
GeneDx Holdings
Feb 24, 2026
Maintains: Buy
Price Target: $200 → $170
Current: $81.38
Upside: +108.90%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $140 → $145
Current: $97.97
Upside: +48.00%
Exagen
Feb 17, 2026
Maintains: Buy
Price Target: $15 → $10
Current: $3.80
Upside: +163.16%
Personalis
Feb 11, 2026
Maintains: Buy
Price Target: $12 → $13
Current: $9.03
Upside: +43.96%
Adaptive Biotechnologies
Feb 6, 2026
Maintains: Buy
Price Target: $21 → $22
Current: $16.46
Upside: +33.66%
IDEXX Laboratories
Feb 3, 2026
Maintains: Buy
Price Target: $830 → $800
Current: $660.71
Upside: +21.08%
MDxHealth
Dec 23, 2025
Reiterates: Buy
Price Target: $7
Current: $3.55
Upside: +97.18%
Castle Biosciences
Dec 12, 2025
Maintains: Buy
Price Target: $38 → $50
Current: $31.88
Upside: +56.84%
Dec 10, 2025
Reiterates: Buy
Price Target: $160
Current: $71.41
Upside: +124.06%
Dec 5, 2025
Maintains: Buy
Price Target: $230 → $260
Current: $216.10
Upside: +20.31%
Dec 3, 2025
Reiterates: Buy
Price Target: $160
Current: $129.76
Upside: +23.30%
Nov 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $103.25
Upside: -
Nov 10, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $4.57
Upside: +53.17%
Sep 10, 2025
Reiterates: Buy
Price Target: $2.5
Current: $1.47
Upside: +70.07%
Aug 25, 2025
Maintains: Sell
Price Target: $6 → $9
Current: $9.71
Upside: -7.31%
Aug 11, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.79
Upside: -
Sep 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.15
Upside: -
May 2, 2024
Maintains: Buy
Price Target: $23 → $21
Current: $10.17
Upside: +106.49%
Mar 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.28
Upside: -
Jan 20, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.60
Upside: -
Sep 22, 2020
Maintains: Hold
Price Target: $350 → $300
Current: $127.40
Upside: +135.48%
Nov 11, 2019
Maintains: Hold
Price Target: $52 → $50
Current: $75.23
Upside: -33.54%
Jul 24, 2019
Maintains: Buy
Price Target: $108 → $112
Current: $211.10
Upside: -46.94%
May 2, 2019
Maintains: Hold
Price Target: $155 → $165
Current: $287.62
Upside: -42.63%
Sep 10, 2018
Maintains: Buy
Price Target: $78 → $80
Current: $22.70
Upside: +252.42%